Our heart failure
therapy solution

FIRST-IN-HUMAN STUDY

Read more

Our heart failure
therapy solution

Our Heart Failure Therapy Solution

Key Facts

Berlin Heals has developed an innovative and disruptive method to treat heart failure, the number one cause of death worldwide. In comparison to other devices, our pilot study indicates that our implantable microcurrent device results in an extremely low level of side effects with comparable clinical effects.

Berlin Heals Holding AG is a Swiss joint stock company founded in 2014 by a serial medical entrepreneur in the field of heart failure treatment.

Berlin Heals has developed a novel implantable electroceutical device with the aim to treat heart failure using electrical microcurrent to induce a progression from reverse modeling to true myocardial recovery.

Heart failure is a generic tearm that describes the condition of a heart that is no longer able to pump a sufficient amount of blood to supply all organs with the necessary level of oxygen.

Heart failure is progressive, making it more difficult to treat over time. It leads to death or highly invasive, burdensome, and costly procedures in its end-stage.

The potential global market demand for our device is tremendous, as it offers a treatment option for patients with heart failure who cannot yet be adequately treated because they either do not meet the criteria for an implantation or because the ensuing side effects are detrimental.

Berlin Heals has developed a novel implantable electroceutical device with the aim to heal heart failure.

Our cardio microcurrent device (C-MIC) has the potential to establish a new, affordable standard of treatment for heart failure.


WE HAVE INITIATED A DUAL CENTER PILOT STUDY WITH LAST PATIENT OUT IN APRIL 2020.

C-MIC DEVICE

C-MIC is by far the most promising treatment for heart failure. There is no comparable application known to us.

  • C-MIC is a Place And Forget (PAF) device
  • Implantation is a low invasive procedure, taking less than one hour
  • Virtually no follow-up necessary
  • Secure wireless programmability
  • Improvement of NYHA classification by 2 grades
  • Reduction of hospitalization per year
  • Cost reduction of heart failure treatment
  • First relevant signs of overall improvement within 4 weeks

Play Video

Heart failure occurs when the heart muscle is unable to pump enough blood through the heart to meet the body's needs for blood and oxygen. Heart failure usually results in an enlarged heart. At first the heart tries to make up for this by:

  • Enlarging to pump more blood.
  • Developing more muscle mass to let the heart pump more strongly, at least initially.
  • Pumping faster to increase the heart’s output. The body also tries to compenste in other ways.
  • The blood vessels narrow to keep the blood pressure up, trying to make up for the heart's loss of power.
  • The body diverts blood away from less important tissues and organs (e.g., kidneys, the heart and brain).
  • Heart failure is progressive, making it more difficult to treat over time.
  • It leads to death or highly invasive, burden-some, and costly procedures in its end stage.
  • Patients may be able to continue leading a stable life for a few years after the initial episode of heart failure thanks to optimal medication or to an ICD (Implantable Cardiac Defibrillator) or CRT-D (Cardiac Resynchronization Therapy) implant.
  • Once medication is no longer effective, a heart transplantation may have to be considered.
  • Chronic heart failure consistently remains a leading cause of death worldwide.
  • Mortality remains unacceptably high (death within 5 years for 50% of patients), despite the availability of optimized medical therapy and numerous devices.
  • More than 26 million people suffer from heart failure worldwide.
  • There is currently no curative solution available other than heart transplantation.

Heart failure occurs when the heart muscle is unable to pump enough blood through the heart to meet the body's needs for blood and oxygen. Heart failure usually results in an enlarged heart. At first the heart tries to make up for this by:

  • Enlarging to pump more blood.
  • Developing more muscle mass to let the heart pump more strongly, at least initially.
  • Pumping faster to increase the heart’s output. The body also tries to compenste in other ways.
  • The blood vessels narrow to keep the blood pressure up, trying to make up for the heart's loss of power.
  • The body diverts blood away from less important tissues and organs (e.g., kidneys, the heart and brain).
  • Heart failure is progressive, making it more difficult to treat over time.
  • It leads to death or highly invasive, burden-some, and costly procedures in its end stage.
  • Patients may be able to continue leading a stable life for a few years after the initial episode of heart failure thanks to optimal medication or to an ICD (Implantable Cardiac Defibrillator) or CRT-D (Cardiac Resynchronization Therapy) implant.
  • Once medication is no longer effective, a heart transplantation may have to be considered.
  • Chronic heart failure consistently remains a leading cause of death worldwide.
  • Mortality remains unacceptably high (death within 5 years for 50% of patients), despite the availability of optimized medical therapy and numerous devices.
  • More than 26 million people suffer from heart failure worldwide.
  • There is currently no curative solution available other than heart transplantation.

Development Timeline

News / Studies

Electrical Microcurrent

Extensive basic research indicates that electrical current of different ... More

First-In-Human Study

First-In-Human Study is showing significant improvements from the start (7 ... More

heart failure classification

The New York Heart Association classifies the severity of heart failure ... More

16 July 2019 Studies & Publications

Pilot Study with C-MIC

Berlin Heals has started its Pilot Study with its novel C-MIC device at two ... More

01 April 2019 Berlin Heals

JHLT journal publication

Berlin Heals presents at the Annual Meeting of the International Society of ... More

Dr Johannes Mueller, MD

Our Co-founder, Dr J. Mueller, is a highly decorated MD and recognized ... More

21 June 2017 Berlin Heals

ASAIO conference 2017 in Chicago

Berlin Heals invited to present C-MIC technology and pre-clinical results ... More

microcurrent can heal

Dr J. Mueller conducted experiments early on to prove that microcurrent can ... More

17 September 2016 Studies & Publications

Effects of Microcurrent

Read the Latest Paper on Effects of Microcurrent, published in ESC Heart ... More

Berlin Heals Holding AG

Berlin Heals Holding AG is a life science company located in Zug, Switzerland with an R&D-branch company - Berlin Heals GmbH - in Berlin, Germany.

Dr Johannes Mueller

Co-founder and Chairman of Berlin Heals Holding AG and Co-CEO of Berlin Heals GmbH

Dr Mueller is a physician and also holds a Master of Engineering from the Technical University of Berlin. He was a physician at the Department of ... Cardiac Surgery at the German Heart Institute Berlin for almost 20 years, the last eight of which as Senior Physician of the Cardiac Surgery Department. Amongst other companies, he founded Berlin Heart in 1997, in which he was member of the BOD and CEO. Upon leaving the Company in 2010, he presided over more than 240 employees. Dr Mueller has published multiple scientific papers and has received many national and international awards for innovation. More

Marko Bagaric

Co-founder, CEO, and Board Member of Berlin Heals Holding AG

Marko Bagaric is responsible for the Company’s general business development and investor relations. At the age of 22 he founded his own business ... and started to gather insights in the real estate and financial sectors. He brings substantial knowhow in private equity and corporate investment. Since the establishment of his own company, Minerva Partners AG in 2011, he has repeatedly demonstrated his ability to support entrepreneurs with financing and management needs. Over the last ten years his focus has been on the health sector where he has co-launched and successfully advised a number of startups. More

Dr Peter Goettel

Co-founder and Co-CEO of Berlin Heals GmbH

Dr Peter Goettel is a physician and holds an engineering degree in Medical Computer Sciences from the University of Applied Sciences, Berlin. He was ... trained in heart surgery at the Charité Medical Center and at the German Heart Institute. Later he spent 10 years with Berlin Heart GmbH where he was involved in the development, clinical evaluation, and market introduction of the world’s first magnetically levitated rotary blood pump for the treatment of heart failure patients. He also introduced the Company’s pediatric mechanical circulatory support system into the US market and was head of the global sales department. More

Reto Moro

Investor, Board Member of Berlin Heals Holding AG

Reto Moro has extensive experience in the banking sector, first with Citicorp Investment Bank followed by Merrill Lynch Capital Markets and Salomon ... Brothers Finanz AG. He founded RTM Financial Coaching AG in 1996, a company successfully active in the areas of asset management, investment counseling, and financing. Mr. Moro is a profound specialist in capital market issues for solutions sought by sophisticated private clients with regards to their portfolio management needs. Due to his vast network, Reto Moro has successfully contributed to the financing needs of various venture capital firms. More

Advisory Board

Prof Dr Volkmar Falk

Member of the Scientific Advisory Board, Medical Director German Heart Institute, Berlin, Germany

Dr Nazmi Krasniqi

Member of the Scientific Advisory Board, Head of Cardiology, Angiology and Rhythmology, Kantonsspital Wetzikon, Switzerland

Prof Dr Urs Eriksson

Member of the Scientific Advisory Board, Medical Director and Chief of Internal Medicine, Kantonsspital, Wetzikon, Professor of Cardiology, University of Zurich, Switzerland

Dr Ulf Berg

Seasoned manager and partner at BLR & Partners from Thalwil, Switzerland; Acts as strategic advisor to the Board of Directors of Berlin Heals Holding AG

Prof Dr Karin Macfelda

Member of the Scientific Advisory Board, Head of Cell Culture Unit, Dept. of Biomedical Research, Medical University Vienna, Austria

Information Request

Want to know more about us? We will be pleased to provide you with further information. Please fill in the following form.